This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Spectrum CEO Has Unhealthy Obsession With Short Sellers

HENDERSON, Nev. (TheStreet) -- Spectrum Pharmaceuticals (SPPI) CEO Raj Shrotriya is obsessed with short sellers. It's not a healthy pastime for him or his company.

Shrotriya has been unable to produce business results strong enough to convince shorts to cover their Spectrum positions, which have been rising steadily all year and now represent about 60% of the company's freely traded shares.

So, in what looks like a desperation move, Shrotriya has orchestrated a year-end, special cash dividend of 15 cents per share payable to the company's shareholders.

Call it Spectrum's Christmas short-squeeze special.

Maybe the dividend ploy will work, at least in the short term. Spectrum shares reacted well this morning, up 3% to $11.10.

Longer term, investors generally see through cynical moves likes this and start to worry about what Spectrum is trying to hide. The granting of a special dividend at the end of the year could easily be a warning of weak fourth-quarter earnings.

Recent Fusilev sales don't inspire confidence, with $25.4 million in October sales reported by Wolters Kluwer, down from $26.1 million in September, which was down from $29.7 million in August. That's a trend heading in the wrong direction. [November sales will be reported next Wednesday.]

Don't forget, too, that Sagent Pharmaceuticals only recently began supplying the market with generic leucovorin, which could be stunting Fusilev growth.

Spectrum posted disappointing third quarter revenue and product sales that were flat sequentially and the company's 2012 guidance implies paltry 3% revenue growth for the December quarter.

If Shrotriya is looking for reasons to explain his company's high short interest and poor stock performance (down 26% year to date), he may want to look internally.

Cursing at short sellers makes for great theater but is generally not a viable business model.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,079.57 -42.44 -0.25%
S&P 500 1,996.74 -3.38 -0.17%
NASDAQ 4,557.6950 -11.9260 -0.26%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs